According to the Zhitong Finance App, Tibet Pharmaceutical (600211.SH) released its 2023 annual report, achieving operating revenue of 3.134 billion yuan, an increase of 22.69% over the previous year. Achieved net profit of 801 million yuan attributable to shareholders of listed companies, an increase of 116.56% over the previous year. Achieved net profit of 784 million yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 112.49% over the previous year. Cash of 7.37 yuan (tax included) is distributed to all shareholders for every 10 shares, while 3 shares are added for every 10 shares using the capital reserve fund.
During the reporting period, operating income increased by 22.69%, and net profit to mother increased by 116.56%. The main reasons are as follows: 1. Financial expenses decreased by 885.60% year on year, mainly due to rising interest rates on US dollar deposits and an increase in interest income from corporate bank deposits. 2. Other income increased by 2,821.15% over the same period last year, mainly due to an increase of 183.46 million yuan in industrial support funds received from the Shannan Happy Home Construction Administration and an increase of 161.18467 million yuan in net profit to mother.